Global Fund Cuts Deals for Cheaper Malaria Drugs

Norvartis and five other drug makers agree to sell malaria drugs at reduced prices. Photo by: -Andrew- / CC BY -Andrew-CC BY

The Global Fund to Fight AIDS, Tuberculosis and Malaria has a reached agreements with six drugmakers to lower the prices of malaria medicines they sell.

The public-private collaboration will benefit children in eight countries in sub-Saharan Africa and Asia, according to a Global Fund press release.

“These agreements bring us closer to the day when all who need malaria medicines will get them at affordable prices,” according to Global Fund Executive Director Michel Kazatchkine.

The six pharmaceutical firms are Ajanta Pharma, Cipla, Guilin, Ipca, Novartis and Sanofi-aventis. The partnership forms part of the first phase of the Affordable Medicines Facility-malaria or AMFm.

AMFm is an innovative mechanism managed by the Global Fund with the help of UNITAID and the U.K. Department for International Development. It aims to provide access to artemisinin-based combination therapies, or ACTs, which are considered the most effective malaria treatment.

Under the deals, private importers will pay as much as 80 percent less than what they paid in 2008 and 2009 for ACTs. AMFm will then subsidize purchases of first-line buyers, all of whom have agreed to pass the benefit of low prices down the supply chain, the Global Fund said.

About the author

  • Chiden Balmes

    Chiden, a correspondent based in Seoul, focuses on computer-assisted reporting to provide international development professionals with practical business and career information. He also contributes to the Development Newswire and the Global Development Briefing, two of the world's highest-circulation development publications.